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The finding in colon carcinoma that cancerogenesis is a sequence of activation of different oncogenes 
and inactivation of tumor suppressor genes has increased the efforts to identify the genes that are 
responsible for the progression of different kinds of cancer. Many activated oncogenes and inactivated 
tumor suppressor genes have been detected in cancer cells during the last decades, but for most 
cancers no network or sequence of oncogenes could be identified that could explain the progression of 
the disease and allow a molecular staging of the disease. Several strategies have been tried to find the 
genes that make cancer cells different from their normal counterparts, however, mostly only with little 
success. In this review article it will be reported how the strategy of transcription factor profiling helped 
to identify the genes that are responsible for the progression of two kinds of cutaneous lymphomas: 
Mycosis fungoides and the Sézary syndrome. By this way we were able to identify several agents that 
may be the prototypes of new drugs to fight these diseases. 
 
Key words: Signal transduction, oncogenes, electrophoretic mobility shift, transcription factor ELISA, tyrosine 
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INTRODUCTION 
 
Cutaneous T cell lymphomas 
 
Cutaneous T cell lymphomas (CTCL) comprise a 
spectrum of lymphoproliferative disorders of the skin 
(Dummer et al., 2006). They affect mostly individuals 
over 50 years, but also younger people. The most 
frequent forms are mycosis fungoides (MF) and its 
leukemic counterpart, the Sézary syndrome (SS). MF 
evolves through several clinical stages (patch, plaque, 
and tumor stage) and leads ultimately to death often 
caused by rapidly growing and ulcerating tumours as well 
as by immune disorders. Lymph nodes are infested in 
later stages and infestation of inner organs is rare. The 
median survival time of MF patients is 8 - 20 years. 
Characteristics of the Sézary syndrome are generalised 
erythroderma, pruritus, dry skin, scaling especially at the 
palms, leukemic T cells in the blood and a shorter life 
expectancy (average 3 - 5 years). This is probably due to 
the circulating malignant T cells, which produce cytotoxic 
T cells, suppressing interleukins like IL-10 in high 
amounts. At the moment there is no therapy to cure both 
forms of CTCL. In early stages CTCL is often misdiag- 
nosed as eczema or psoriasis. Hyper- and 
hypopigmentation have also been found for MF and SS. 
Some clinical features of MF and SS can also occur in a 
transient stage of adult T-cell leukemia (ATL), which is 
caused by HTLV-I (Nagatani et al. 1994; Bunn and Foss 
1996) and has a much more aggressive course. This has 
led to the erroneous assumption that HTLV may be 
involved in CTCL, which has been meanwhile disproved 
(Döbbeling, 2002 and references cited therein). The 
incidence of CTCL in the United States is 6.4/million/year 
(Criscione et al., 2007). The incidence in Afro-Americans 
has been found to be higher than in white Americans 
(9.0/million/year and 6.1/million/year respectively). How-
ever, it has to be kept in mind that MF and SS are 
clinically more difficult to discern from ATL on black skin. 
This has also been highlighted by the study  of  Fouchard 
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Figure 1. Schematic representation of the different steps of signal 
transduction and gene activation in the cell.  
 
 
 
et al. (1998) in Mali. ATL cases may have been 
misdiagnosed as CTCL at times, when several immune 
histochemical and molecular biology methods have not 
yet been available (Bunn and Foss, 1996). These 
misdiagnoses may have also led to the conclusion that 
CTCL progresses more aggressively in Africans and 
Afro-Americans, since ATL progresses generally more 
aggressively than MF and SS.  
MF patients in early stages are generally treated with 
glucocorticoids or more effectively with psoralen and 
subsequent UVA treatment (PUVA). PUVA therapy 
shows complete remission for 6 - 30 months in more than 
80% of the patients. However all patients relapse. 
Advanced stages and Sézary syndrome are treated by 
PUVA plus interferon alpha or retinoids, extracorporal 
photopheresis, total skin electron beam irradiation or 
chemotherapy (e.g. low dose methotrexate, chlorambucil 
plus prednisone, retinoids, interferon alpha, (Dummer et 
al., 2007). All these treatments lead to partial or total 
remission, but not to a final cure of the disease. 
 
 
Molecular cancerogenesis 
 
It has been shown for colon carcinoma that canceroge-
nesis is a multistep process which involves the mutation 
of several oncogenes and anti-oncogenes (Vogelstein et 
al., 1993). Many oncogenes are involved in signal trans-
duction  (e.g. src, ras, raf) and are often transcription  
factors  (e.g.  c-fos,  c-jun,  c-myc),   which promote the 
entry of cells into a new replication cycle. Tumor suppres-
sor genes are either regulators of the cell cycle 
preventing cells from uncontrolled growth (e.g. Rb, c-abl, 
p21, p16), or transcription factors, which enhance the 
transcription of these genes (e.g. p53). The expression of  
 
 
 
 
proto-oncogenes is normally strictly regulated and does 
not lead to tumorigenesis. Only mutants of these genes 
which cannot be properly regulated gain a tumorigenic 
potential. Wild type oncogenes that function normally in 
contrast to their mutated forms are called proto-
oncogenes. 
There are different kinds of oncogenes. Many 
oncogenes code for molecules that are involved in signal 
transduction, these include growth factor receptors (e.g. 
EGF, PDGF receptors), tyrosine kinases (Jak, c-abl, c-
src), serine/threonine kinases (raf, c-mos) and transcript-
tion factors (c-jun, c-fos, c-rel). The first step of a typical 
signal transduction pathway is that a growth factor binds 
to its receptor on the cell membrane. This leads to 
changes of the molecular structure of the receptor 
molecule (e.g. EGF, PDGF receptor), and the activation 
of a tyrosine kinase, which is part of the receptor 
molecule. In the case that the receptor does not possess 
a tyrosine kinase activity it can recruit directly or via 
adaptor molecules free tyrosine kinases to the 
receptor/ligand complex (e.g. Jak, c-abl, c-src). The 
activated tyrosine kinases then activate serine/threonine 
kinases, which activate transcription factors by phosphor-
rylation. These activated transcription factors are now 
able to move to the nucleus and to bind to their target 
sequences on the DNA. Here they help to recruit co-
factors of RNA polymerase to the promoter and to form 
an active transcription complex (Figure 1). This scheme 
has many variations e.g. some tyrosine kinases can 
directly activate transcription factors and sometimes a 
whole cascade of serine/threonine kinases (MAPKKK 
pathways) may be required for transcription factor 
activation. 
In cancer mutations of signalling transducing molecules 
(receptors, tyrosine kinases, serine/threonine kinases, 
and transcription factors) can mimic a stage of permanent 
stimulation. The replacement of a tyrosine residue in 
tyrosine kinases, which often phosphorylate themselves, 
by an acidic amino acid (glutamic acid, aspartic acid) can 
lead to a permanently active tyrosine kinase molecule, 
since the negative charge of the acidic amino acid mimics 
the negative charge, which is normally introduced by the 
addition of a phosphate molecule to the tyrosine residue. 
Such a mutant would constitutively activate transcription 
factors, which in turn can activate genes that are 
necessary for proliferation and cell survival (e.g. bcl-2). 
Constitutive tyrosine kinase can also be achieved by the 
loss of a regulatory domain of the enzyme by deletion or 
missense mutants. The same types of mutations can also 
occur in serine/threonine kinases and transcription 
factors. 
Every signalling pathway activates only a certain sub-
sets of transcription factors. Thus it is possible to identify 
a disturbed signalling pathway by the determination of 
abnormal constitutive transcription activities in a cancer 
cell.  There   are  inhibitors  of  tyrosine   kinases,  serine/  
  
 
 
 
threonine kinases and transcription factors, which can 
serve as prototypes of future anti-cancer drugs. One 
example is Imatinib (Gleevec, STI157), which inhibits the 
tyrosine kinases c-abl and c-kit. It is effective against 
chronic myeloic leukemia (CML) (Deininger et al., 2005) 
and gastro-intestinal stromal tumors (GIST) (Schnadig 
and Balanke, 2006). 
 
 
Detecting differences in gene expression in cancer 
and normal cells 
 
The first strategy to detect genes that are involved in 
cancerogenesis was the construction of subtraction 
libraries. The basic principle was that the total m-RNA of 
one cell type was hybridized to the c-DNA library of 
another cell type and c-DNAs that did not hybridize and 
remained single stranded were cloned (Schweinfest et 
al., 1990). This method was quite successful when cells 
of different tissues were compared, but yielded often 
disappointing results, when cancer cell lines and the 
corresponding cells were compared. 
The technically most sophisticated method to detect 
differences in gene expression in normal and cancer cells 
is expression profiling using DNA microarrays that are 
also known as gene chips. On one gene chip thousands 
of single stranded DNA oligonucleotides that represent 
sequences of genes are spotted and chemically linked to 
a chemical matrix (glass, plastic, silicon). The c-DNA 
libraries from two different cell types or cell lines that 
have been labelled with two different fluorescent dyes are 
hybridized to the chips. The binding of the differently 
labelled probes to a given spot results in an individual 
colour of each spot. From the different colours of the 
spots it can be deduced which gene more or less 
expressed in the analyzed cell lines. The exact 
determination of the wavelengths of the colours of the 
individual spots and the evaluation of the relative 
abundances of the investigated genes needs a lot of 
hard- and software for the evaluation. This method is 
therefore very expensive. The initial results were disa-
ppointing and little reproducible, since the comparison of 
the same cell lines with the gene chips of different 
suppliers yielded different results. This has meanwhile 
improved and the results that have recently been 
obtained for MF and SS cells (Mao et al., 2003; Mao et 
al., 2008; Vermeer et al., 2008; van Doorn et al., 2008) 
are reliable, since beside the identification of genes that 
expressed differently in MF and SS they could also 
reproduce findings that have been made before by the 
following method (Qin et al., 1999; Zhang et al., 2003; 
Zhang et al., 2007).   
 
 
The strategy of transcription factor profiling 
 
Transcription factors transmit the information  of  cell  sig-  
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nalling to gene expression. They bind to specific DNA 
sequences around the coding sequence of the target 
gene and recruit RNA polymerases to the start point of 
gene transcription. Cancer cells have constitutive 
activities of transcription factors, which are inactive in 
normal cells. They receive activation signals from either 
mutated or otherwise deregulated kinases, which mimic 
signals of growth factors. Since only different sets of 
transcription factors are regulated by a given tyrosine or 
serine/threonine kinase, the identification of an abnormal 
transcription factor activity can be traced to a limited 
number of tyrosine and serine/threonine kinases, which 
then can be tested separately for their activities. Since 
each transcription factor regulates only a limited number 
of genes that favour the proliferation and survival of 
cancer cells, an aimed search for these target genes is 
possible. 
 
 
METHODS USED IN TRANSCRIPTION FACTOR 
PROFILING  
 
Preparation of nuclear extracts 
 
To provide a transcription factor profile of a cancer cell 
line it is necessary to prepare protein extracts of the cell 
nucleus, which contains the transcription factors. A 
simple method to obtain such nuclear extracts has been 
developed by Gerber et al. (1992). The principle is that 
the cells are swollen in a hypotonic buffer and then lysed 
by a detergent. The nuclei are obtained by centrifugation 
and after the removal of the supernatant they are 
extracted by a high salt buffer. After the extraction the 
nuclei are removed and the supernatant containing the 
transcription factors can be stored at -80 or -190°C. 
 
 
Electrophoretic mobility shift assay (EMSA) 
 
The EMSA or band shift is a quite old method, which has 
already been used for DNA binding proteins of bacteria. 
The adaptation of this assay to eukaryotic cells has 
helped a lot to identify eukaryotic transcription factors. 
The principle is that a radioactively or otherwise labelled 
double stranded DNA-oligonucleotide that con-tains the 
binding sequence of a certain transcription factor is 
incubated in the nuclear extract of a cell line of interest. 
After the binding reaction of transcription factor to the 
DNA has completed the mixture is loaded on non-
denaturing polyacrylamide gel and the DNA and the 
transcription factor/DNA complexes are separated from 
the unbound DNA oligonucleotide by electrophoresis, 
since the transcription factor/DNA complexes migrate 
more slowly than the free DNA oligonucleotide. The 
presence of such complex confirms the presence of a 
transcription factor, but does not tell exactly which 
transcription factor it is, since nearly all  transcription  fac-  
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Figure 2. Sample of EMSA experiments with nuclear extracts of a) 
HUT78 (Sézary syndrome) and b) MyLa 2059 (Mycosis fungoides) 
cell lines and a DNA oligonucleotide containing the binding site of 
NFkB proteins. Lanes 1: negative control (untreated HeLa cervix 
carcinoma cells), lanes 2: positive control (phorbol ester treated 
HeLa cells). Lanes 3: untreated HUT78 (a) and MyLa 2059 (b) cells 
without antibodies, Lanes 4: untreated HUT78 (a) and MyLa 2059 
(b) cells incubated with an antibody against NFkB p50, lanes 5: 
untreated HUT78 (a) and MyLa 2059 (b) cells incubated with an 
antibody against NFkB p65. Supershift: DNA/protein/antibody 
complex. Shift: DNA/protein complex. Unspec: unspecific DNA/ 
protein complexes containing highly abundant proteins that bind 
sequence-independently to DNA. The gel with the MyLa 2059 cell 
nuclear extracts has been run longer for better resolution, so that 
the free unbound DNA has already passed through the gel.  
 
 
 
tors belong to gene families, whose gene products often 
bind to the same DNA sequence. An exact identification 
of the transcription factor can be obtained, when a spe-
cific antibody against the supposed transcription factor is 
added to the nuclear extract and the DNA-oligonucleotide 
mixture. This leads to the formation of DNA/transcription 
factor/antibody complexes, which migrate on the 
polyacrylamide even more slowly produce a so called 
supershift (Figure 2). However, sometimes this trimeric 
complex is too unstable and cannot be seen on the gel. 
 
 
Transcription factor ELISA (TF ELISA) 
 
The difficulties with unstable DNA/transcription factor/ 
antibody complexes can be overcome by the TF ELISA. 
The principle is that the DNA-oligonucleotide containing 
the DNA binding sequence of the transcription factor of 
interest is attached to the surface of a 96 well plate. 
Equal amounts of nuclear extracts of the cells of interest 
are added to the wells and the transcription factor of 
interest binds to its DNA motif. After the binding reaction 
has completed the remaining proteins are washed away. 
Then an antibody against the transcription factor is 
added. When the antibody has bound to its target a 
horseradish peroxidase (hrp) conjugated second antibody 
is added, which is directed against the constant region of  
 
 
 
 
the first antibody. The addition of the hrp substrate to the 
well starts a colour reaction, which allows the measure-
ment of the DNA-bound transcription factor by an ELISA 
reader. This method allows measuring many transcription 
factors and cell lines on plate at the same time. 
Taken together these methods need less apparatuses, 
do not depend on sophisticated software, and are there-
fore more robust and less expensive. 
 
 
IDENTIFICATION CONSTITUTIVE TRANSCRIPTION 
FACTOR ACTIVITIES IN MF AND SS BY 
TRANSCRIPTION FACTOR PROFILING 
 
The NFkB transcription factor gene family 
 
To profile mycosis fungoides and the Sézary syndrome, 
first the NFkB transcription factor family was analyzed. A 
screening of various B and T cell lymphomas (Frachiolla 
et al., 1993) had shown that 10 - 15% of CTCLs and the 
SS cell line HUT78 contain a chromosomal translocation 
of the NFKB2 (lyt-10) gene, which codes for the 
transcription factor NFKB2 (Neri et al., 1991; Schmid et 
al., 1991), also called p52. HUT 78 cells produce a 
truncated NFKB2 protein that is constitutively located in 
the nucleus (Zhang et al., 1994) since it lacks large parts 
of its regulatory region that retains it in the cytoplasm and 
thus prevents it to move into the nucleus and to bind to its 
target sequences on the DNA. This modified transcription 
factor therefore may act like other oncogenes (e.g. v-jun, 
v-Rel) as a permanently active transcription factor which 
disturbs normal gene expression.  
NFKB2 belongs to the rel/dorsal/IkB superfamily of 
transcription factors, which consists of three groups 
(Baldwin 1996, Ghosh et al., 1998, Karin and Ben-Neriah 
2000). Group I consists of proteins of about 65 kD (cRel, 
RelA, RelB) containing the rel-domain, which is 
necessary for DNA binding, activation of transcription and 
interaction with other members of the rel/dorsal/IkB-
superfamily. Group II consists of the genes NFKB1 and 
NFKB2, which code for proteins of 105 and 100 KD 
respectively (p105 and p100). They contain a rel domain, 
an acidic region, and seven ankyrin repeats that tether 
these proteins to the cell membrane. The group II 
proteins p105 and p100 are processed by a protease into 
the transcriptionally active proteins p50 (NFKB1) and p52 
(NFKB2) respectively, which lack the ankyrin repeats. 
The activity of the p100 processing protease depends on 
the activity of the IkB kinase alpha (IKK alpha) 
(Senftleben et al., 2001). Group III consists of the IkB 
proteins, which also contain seven ankyrin repeats and 
an acidic region, and resemble the carboxyl terminal 
parts of p105 and p100 proteins, which are cut off by a 
protease. The p50/p65 and p52/RelB proteins 
respectively form heterodimers that migrate into the 
nucleus, bind to NFkB sites on the DNA, and activate 
gene transcription.  Group II  proteins  (p50 and p52)  can  
  
 
 
 
also form homodimers that also bind to the NFkB sites. 
They act generally as transcriptional repressors, but act 
sometimes as transcriptional activators, depending on the 
context of transcription factor binding sites in a given 
promoter or enhancer, and on the presence of cell 
specific co-factors (Kurland et al., 2001). The IkB proteins 
(group III) bind to group I/II heterodimers and sequester 
them to the cytoplasm, blocking thus the activation of 
gene transcription by NFkB. When an NFkB activating 
stimulus is given IkB proteins are phosphorylated by the 
IkB kinase beta (IKK beta) complex and subsequently 
ubiquitinylated and degraded (Zandi et al., 1997; 
Woronicz et al., 1997; Rothwarf et al., 1998). An 
exception amongst the IkB proteins is Bcl-3. It forms 
p52/p52/Bcl-3 heterotrimers with p52 (Bours et al., 1993), 
which bind to NFkB sites and activate gene transcription. 
Bcl-3 has also been reported to activate transcription by 
the removal of p50/p50 homodimers from NFkB binding 
sites (Franzoso et al., 1992). The NFkB binding sites are 
not occupied by rel/dorsal/IkB proteins in normal cells 
and binding of NFkB proteins occurs only after activation 
by a cellular signal e. g. by a cytokine (IL-1, TNF alpha) 
or a stress signal (hypoxia). However, for many cancer 
cells it has been found that they are state that resembles 
activated cells. 
To profile mycosis fungoides and the Sézary syndrome 
nuclear extracts of mycosis fungoides and the Sézary 
syndrome cell lines were analyzed by electrophoretic 
mobility shift assays (EMSA) and transcription factor 
ELISA (TF-ELISA). Surprisingly all five members of the 
NFkB gene family: p50, p52 (group I), p65, RelB, and c-
Rel (group II) were constitutively active in the tested MF 
and SS cell lines (Qin et al., 1997; Izban et al., 2000; 
Sors et al., 2006). Western blot analysis of the nuclear 
extracts confirmed that all NFkB proteins were of normal 
size with the exception of the p52 protein of the SS cell 
line HUT78, which carries an NFkB2 translocation. The 
Western blots also detected the Bcl-3 protein in the 
nuclear extracts of the tested MF and SS cell lines.  
The immunohistochemical analysis of skin lesions of 
MF and SS patients with specific antibodies shows that 
p50 and Bcl-3 were present in the nuclei of malignant 
cells at the earliest stages of these diseases. The 
proteins p65, p52 and RelB were also found in earlier 
stage, but a simultaneous expression of p52 and RelB 
occurred only in the tumor stage (Döbbeling et al., 2007). 
The c-Rel protein was only found in some tumor stage 
samples. These findings indicate that the MF and SS cell 
lines mirror the tumor stage of MF and SS. 
 
 
The STAT transcription factor gene family 
 
Interleukin 7 (IL-7) and interleukin 15 (IL-15 have been 
found to be growth factors for MF and SS cells (Dalloul et 
al., 1992; Döbbeling et al., 1998a). Since interleukins sig-  
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nal through the Jak and Tyk tyrosine kinases, one can 
assume that the STAT (signal transducer and activator of 
transcription) transcription factors, which are directly 
phosphorylated and activated by Jak and Tyk tyrosine 
kinases, are involved in the pathogenesis of MF and SS. 
The test of the IL-7 and IL-15 independent MF and SS 
cell lines MyLa 2059 and HUT78 indeed detected 
constitutive DNA-binding of the STAT proteins 2, 3, 5 and 
6 in the nuclear extracts of these cell lines. In the IL-7 
and IL-15 dependent SS cell line however, the binding 
activities of these 4 STAT proteins were dependent on 
the presence of these two growth factors in the medium. 
All these four STAT proteins were of the expected size, 
indicating that no chromosomal translocations of these 
transcription factors has occurred. The fact that the MyLa 
2059 and HUT78 have become IL-7 and IL-15 indepen-
dent can therefore be explained by the assumption that a 
mutated or otherwise activated tyrosine kinase has 
become constitutively active in these cells (see below).  
In the biopsies of MF and SS patients activated STAT5 
was already detected in early stages, whereas STAT2, 3, 
and 6 become active only in the tumor stage (Qin et al., 
2001a; Sommer et al., 2004). Recently it was reported 
that STAT3 is also already active in early stages 
(Witkiewicz et al., 2007). These activities may be trigger-
ed by tyrosine kinases that are IL-7 and IL15 independent 
or tyrosine kinases that are activated by IL-7 and IL-15 
produced by skin keratinocytes and fibroblasts or the MF 
and SS cells themselves (Döbbeling et al., 1998a).  
 
 
Constitutively active transcription factors of the 
jun/fos, myc/max and myb gene families  
 
MF and SS cell lines and skin lesions were also tested for 
constitutively active members of the jun/fos, myc/max 
and myb gene families. For the jun/fos family no DNA 
binding activities could be found for the proteins c-Fos, 
Fra-1, Fra-2, and c-Jun, however constitutive DNA bind-
ing activities were reported for JunB (Mao et al., 2003) 
and JunD (Qin et al., 1999). Constitutive DNA binding 
was also observed for the myc/max and myb gene family 
members c-Myc, Max, and c-Myb. No binding was 
observed for N-myc and the mad proteins. The DNA-
binding of JunD and c-myb was dependent on IL-7 and 
IL-15 in SeAx cells, whereas the binding of c-Myc/Max 
heterodimer was independent of IL-7 and IL-15 (Qin et 
al., 1999). In all three tested MF and SS cell lines two 
other IL-7 and IL-15 dependent DNA binding proteins 
were found, which bound like the c-Myc/Max heterodimer 
to the so called E-box DNA element, but did not react 
with c-Myc and Max antibodies. These complexes may 
contain the protein USF-1 and USF-2, since it has been 
reported that these proteins bind to the same recognition 
sequence as c-Myc/Max heterodimers. The c-Myb protein 
was detected in the MF and SS cell lines  and  skin  biop- 
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sies. It could already be detected in early stage skin 
lesions (Qin et al., 2001). 
 
 
Determination of the involved signalling pathways 
 
Several substances are known to inhibit NFkB, STAT and 
Fos/Jun DNA-binding. Sodium salicylate is a potent 
inhibitor of the IKK beta (inhibitor of kappa B kinase beta) 
kinase. This kinase phosphorylates inhibitor of kappa B 
(IkB) proteins at a serine residue and targets it for 
proteolytic degradation. The destruction of the IkBs 
allows the NFkB molecules to enter the nucleus and to 
activate transcription. The addition of sodium Salicylate to 
MF and SS cell line led to a reduction of the constitutive 
NFkB binding and at longer incubation to the apoptosis of 
these cells. This experiment showed that constitutively 
active IKK beta activity is necessary for the maintenance 
of constitutive NFkB activities. The addition of the src-
type tyrosine kinase inhibitor herbimycin A had the same 
effects, indicating that a src-type tyrosine kinase may be 
involved in NFkB and IKK beta regulation, since the 
prototype of these kinases, c-src, has been reported to 
phosphorylate IKK beta (Huang et al., 2003). An immuno-
histochemical screening of MF ands tumors with specific 
antibodies showed that c-src and the related c-yes 
tyrosine kinase are expressed in these tumors. Interest-
ingly c-src is also involved in the activation of STAT 
transcription factors. The expression of c-yes increased 
strongly in the tumor stage (Zhang et al., 2007). C-Src 
was already found in the early stages, however its 
activated (that is, phosphorylated) form was only found in 
the tumor stage. Therefore one can assume that 
interleukin-dependent tyrosine kinases are responsible 
for the phosphorylation of NFkB and STAT protein in the 
early stages, whereas the interleukin-independent c-Src 
kinase takes over this job in the tumor stage. The 
immunohistochemical stainings also revealed the expres-
sion of the tec-type tyrosine kinase bmx (Döbbeling et al. 
2004), which has also been implicated in the activation of 
several STAT molecules (Saharinen et al., 1997). Sodium 
salicylate and herbimycin A could therefore be prototypes 
for novel anti-cancer drugs against MF and SS. In 
contrast to these two agents the NFkB and jun/fos 
antagonist dexamethasone had only a transient effect on 
the IL-7 and IL-15 dependent SS cell line SeAx. PP1, an 
inhibitor of the T cell receptor associated tyrosine kinases 
lck and fyn inhibited the constitutive NFkB activities, but 
had no proliferation inhibiting or cell killing effects, 
indicating that sodium salicylate and herbimycin A may 
have more targets than PP1 (Döbbeling et al., 1998b). 
The IKK complex has also been reported to have an 
influence on the cell cycle. IKK alpha has been reported 
to suppress the cell cycle regulator p27 by the activation 
of p52/RelB heterodimers that activate the skp2 gene. 
The   Skp2  protein  targets  p27  for  ubiquitin-dependent  
 
 
 
 
degradation (Schneider et al., 2006). It is capable to 
inactivate RB by hyperphosphorylation (Li et al., 2003) 
and thus to increase cell cycle progression and 
proliferation. Since RB is hyperphosphorylated in MF and 
SS cell lines and skin lesions (Zhang et al., 2007), this 
could be another explanation of this finding, besides the 
already described inhibition of the p16 tumor suppressor 
gene (Zhang et al., 2007), which controls the phosphory-
lation of RB by cyclin dependent kinases.  
 
 
VALIDATION OF THERAPEUTIC TARGETS BASED 
ON TRANSCRIPTION FACTOR PROFILING 
 
Cell death inhibiting (anti-apoptotic) genes are 
targets of NFkB and STAT proteins 
 
The anti-apoptotic bcl-2 bcl-xL and mcl-1 genes have 
been reported to be regulated by NFkB and STAT 
proteins (Chen et al., 2000; Lord et al., 2000). Indeed the 
inhibition of NFkB and STAT factors by sodium salicylate 
and herbimycin A was paralleled with a reduced expres-
sion of these three genes (Döbbeling et al., 1998b). The 
inhibition of bcl-2, bcl-xL and mcl-1 therefore seems to 
shift the equilibrium of the expression of pro- and anti-
apoptotic genes to the side of the pro-apoptotic genes 
(Nielsen et al., 1999, Zhang et al., 2002). No effect on the 
two agents on the expression on the pro-apoptotic bad 
and bax genes was detected. 
 
 
Inhibitors of bcl-2 gene expression inhibitors are also 
inhibitors of NFkB and STAT in MF and SS cells 
 
It has been reported (Shen et al., 1997) that arsenic 
trioxide (As2O3) that is used against AML (acute myeloic 
leukemia) (Soignet et al., 1998) is an inhibitor of bcl-2. 
Since MF and SS cells express bcl-2, As2O3 was tested 
for its ability to inhibit bcl-2 expression in these cells. 
Indeed non-toxic concentrations of As2O3 (1 – 2 uM) 
suppresses bcl-2 expression and causes apoptosis of MF 
(MyLa 2059) and SS cells (HUT78, SeAx) in cell culture. 
The suppression of bcl-2 was paralleled by a repression 
of the DNA binding of NFkB and STAT protein. Thus the 
suppression of NFkB of STAT transcription factors may 
be the reason for bcl-2 repression. The expression of the 
anti-apoptotic bcl-xL and mcl-1 genes was also suppres-
sed by the addition of As2O3, whereas the expression of 
the pro-apoptotic bax and bad genes remained nearly 
unchanged (Tun Kyi et al., 2008).  
Since As2O3 is a known poison it may be not well 
accepted by patients. Since arsenic and antimony have 
very similar chemical properties, we looked for antimony 
compounds that have already been used for treatment of 
other diseases. Finally we chose potassium antimonyl 
tartrate (PAT), which  has  been  used  for  the  treatment 
  
 
 
 
against schistosoma and leishmania (Davis et al., 1975; 
Roberts et al., 1995) and has been reported to kill cells in 
vitro by oxidative stress (Lecureur et al., 2002). 
Corresponding experiments as with As2O3 showed 
that PAT had the same effects as As2O3 (Qin et al., 
1998). It killed the MF and SS cell lines in vitro, suppres-
sed the DNA binding of NFkB of STAT transcription 
factors and suppressed the expression of the bcl-2, bcl-
xL and mcl-1. The expression of the pro-apoptotic bax 
and bad genes remained also unchanged. The effects 
occurred at concentrations of 5 - 20 uM, depending on 
the cell line and were also observed in melanoma cell 
lines (Döbbeling et al., 1998c). These concentrations 
were 40 - 160 times lower than the LD50. 
Both agents were tested for their effects in vivo. For 
this purpose immune deficient athymic nude mice were 
used, which were injected with MyLa 2059 cells. Tumors 
appeared after 2 – 6 weeks. The minimal concentrations 
to reach total remissions were 0.5 - 1 mM As2O3 and 1 - 
2 mM PAT injected directly into the tumor. Since these 
high concentrations were applied locally, they had no 
toxic side effects. This result indicated hat MF tumor cells 
are much more resistant against anti-cancer agents, 
when they can grow as a tumor. This results explains 
why intravenous application of As2O3 in a 1 -10 uM 
range did not affect skin tumors of Sézary syndrome 
patients although the leukemic cells in the blood were 
killed (Michel et al. 2003).  
 
 
SUMMARY 
 
Numerous proto-oncogenes that are involved in the 
pathogenesis of Mycosis fungoides and Sézary 
syndrome have been identified: c-rel, c-myb, c-myc, junB, 
junD, bcl-2, bcl-3, c-src, c-yes, bmi-1 and ras. Activation 
of c-myb, bcl-2, and bcl-3 occurs already in early stages 
of these diseases and is accompanied by constitutive 
activities of the transcription factors p50, p65, and 
STAT5. The other oncogenes and transcription factors 
described in this article are activated in the later stages. 
The transcription factor profiling of Mycosis fungoides 
and the Sézary syndrome identified the NFkB and STAT 
factors and their signal transduction pathways as targets 
for new drugs for the treatment of these diseases. 
Prototypes of these drugs are the IKK beta inhibitor 
sodium salicylate and the src-type tyrosine kinase 
inhibitor Herbimycin A. Both reagents inhibit the signalling 
through the NFkB and STAT pathways and cause cell 
death by the inhibition of cell survival genes. 
As2O3 and PAT, which have been initially described as 
cell survival (anti-apoptotic) gene inhibitors had the same 
effects on NFkB and STAT activities and cell survival 
gene expression as sodium salicylate and herbimycin A. 
They may therefore also act on the same kinases as 
salicylate and herbimycin A.  The  effects  of  As2O3  and 
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PAT could also be observed in a mouse model for MF 
(Tun Kyi et al., 2008; Tun Kyi et al., unpublished results). 
Experiments in vitro have also shown that As2O3 and 
PAT can also kill other cancer cell types indicating that 
these two agents may also be effective against other 
types of cancer. 
From the data from MF and SS one can conclude that 
the following strategy may be successful for the search of 
new anti-cancer agent: 
 
1. Identify aberrant constitutive transcription factor 
activities in cancer cells. 
2. Determine the involved signal transduction pathways 
and transcription factor targets. 
3. Identify known inhibitors of these pathways and 
targets. 
4. Test these inhibitors in vitro and in vivo. 
5. Look for or develop derivatives of these inhibitors that 
are more effective and less toxic. 
 
Transcription factor profiling is also a useful tool to 
investigate the pathogenesis of cancers. 
It could be shown that the different NFkB and STAT 
transcription factors are activated at different stages of 
the diseases. This allows determining how the diseases 
have progressed and which treatment may the most 
suited one for the individual patient. 
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